Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer
To study the value of adjuvant tamoxifen (TAM) in premenopausal women with oestrogen receptor (ER)-positive breast cancer who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) polychemotherapy. Methods: Four hundred and two premenopausal ER-positive breast cancer patients who...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2003-07-01
|
Series: | Asian Journal of Surgery |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1015958409603778 |
id |
doaj-c9f5b8f9d7f546e6a0afcede7e6d4f37 |
---|---|
record_format |
Article |
spelling |
doaj-c9f5b8f9d7f546e6a0afcede7e6d4f372020-11-24T22:31:10ZengElsevierAsian Journal of Surgery1015-95842003-07-0126316316810.1016/S1015-9584(09)60377-8Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast CancerHe-Cheng LiXian-Feng WenYi-Feng HouKun-Wei ShenJong WuJing-Song LuZhen-Zhou ShenZhi-Ming ShaoTo study the value of adjuvant tamoxifen (TAM) in premenopausal women with oestrogen receptor (ER)-positive breast cancer who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) polychemotherapy. Methods: Four hundred and two premenopausal ER-positive breast cancer patients who received CMF chemotherapy between January 1990 and December 1999 were retrospectively studied. Disease-free survival (DFS) and overall survival (OS) were used to evaluate the clinical value of TAM therapy. The relationships between nodal status and TAM were also analysed. Results: After a mean of 41 months of follow-up, 43 (13.7%) patients died of breast cancer and 68 (19.9%) patients suffered recurrence. There was a significant difference between TAM and non-TAM treatment groups for DFS (p = 0.0058), but no significant difference for OS. For node-negative patients, there was no significant difference between the TAM and non-TAM treatment groups for either DFS or OS. For node-positive patients, the difference between TAM and non-TAM treatment groups was significant for both DFS and OS (p = 0.0497 and p = 0.0285, respectively). Conclusion: TAM resulted in additional benefit to premenopausal patients with node-positive ER-positive breast cancer who received the CMF polychemotherapy regimen.http://www.sciencedirect.com/science/article/pii/S1015958409603778 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
He-Cheng Li Xian-Feng Wen Yi-Feng Hou Kun-Wei Shen Jong Wu Jing-Song Lu Zhen-Zhou Shen Zhi-Ming Shao |
spellingShingle |
He-Cheng Li Xian-Feng Wen Yi-Feng Hou Kun-Wei Shen Jong Wu Jing-Song Lu Zhen-Zhou Shen Zhi-Ming Shao Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer Asian Journal of Surgery |
author_facet |
He-Cheng Li Xian-Feng Wen Yi-Feng Hou Kun-Wei Shen Jong Wu Jing-Song Lu Zhen-Zhou Shen Zhi-Ming Shao |
author_sort |
He-Cheng Li |
title |
Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer |
title_short |
Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer |
title_full |
Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer |
title_fullStr |
Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer |
title_full_unstemmed |
Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer |
title_sort |
addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer |
publisher |
Elsevier |
series |
Asian Journal of Surgery |
issn |
1015-9584 |
publishDate |
2003-07-01 |
description |
To study the value of adjuvant tamoxifen (TAM) in premenopausal women with oestrogen receptor (ER)-positive breast cancer who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) polychemotherapy.
Methods: Four hundred and two premenopausal ER-positive breast cancer patients who received CMF chemotherapy between January 1990 and December 1999 were retrospectively studied. Disease-free survival (DFS) and overall survival (OS) were used to evaluate the clinical value of TAM therapy. The relationships between nodal status and TAM were also analysed.
Results: After a mean of 41 months of follow-up, 43 (13.7%) patients died of breast cancer and 68 (19.9%) patients suffered recurrence. There was a significant difference between TAM and non-TAM treatment groups for DFS (p = 0.0058), but no significant difference for OS. For node-negative patients, there was no significant difference between the TAM and non-TAM treatment groups for either DFS or OS. For node-positive patients, the difference between TAM and non-TAM treatment groups was significant for both DFS and OS (p = 0.0497 and p = 0.0285, respectively).
Conclusion: TAM resulted in additional benefit to premenopausal patients with node-positive ER-positive breast cancer who received the CMF polychemotherapy regimen. |
url |
http://www.sciencedirect.com/science/article/pii/S1015958409603778 |
work_keys_str_mv |
AT hechengli additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT xianfengwen additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT yifenghou additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT kunweishen additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT jongwu additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT jingsonglu additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT zhenzhoushen additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer AT zhimingshao additionofadjuvanttamoxifentocyclophosphamidemethotrexateand5fluorouracilforpremenopausalwomenwithoestrogenreceptorpositivebreastcancer |
_version_ |
1725738408208236544 |